Xenon Pharma
NASDAQ: XENE423 employees on LinkedIn · 3 known investors
Find your way into Xenon Pharma
1,351 people in our graph share verified history with the Xenon Pharma team — schools, employers, funds. One of them is your warm intro.
Mojca Skoberneunlockedknows Andrea DiFabio · together at Repertoire Immune Medicines (overlapped)
knows the team · via Repertoire Immune Medicines
knows the team · via University of Pennsylvania
knows the team · via EMD Serono
knows the team · via Bucknell University
knows the team · via Bayer
Xenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders. Its pipeline includes a Phase 3 program in epilepsy and depression for its lead candidate azetukalner, along with early-stage pain programs targeting sodium and potassium channels.
Founders & leadership
IM
Ian MortimerinPresident and Chief Executive Officer
DC
Darren ClineinChief Commercial OfficerDarren Cline is Chief Commercial Officer at Xenon Pharmaceuticals, a neuroscience-focused biopharmaceutical company developing ion channel modulators for neurological and psychiatric disorders. Previously, he served as CEO of Epygenix Therapeutics, where he led a rare disease epilepsy portfolio through late-stage development.
AD
Andrea DiFabioinChief Legal Officer and Corporate SecretaryAndrea DiFabio is Chief Legal Officer and Corporate Secretary of Xenon Pharma, a neuroscience-focused biopharmaceutical company developing ion channel modulators for neurological and psychiatric disorders. He brings experience in public company M&A, securities law, licensing, intellectual property matters, and pharmaceutical product commercialization.
JE
James EmpfieldinExecutive Vice President, Drug DiscoveryJames Empfield held senior drug discovery and medicinal chemistry leadership roles at both biotech and pharmaceutical companies, including leading a research organization of over 200 scientists and establishing a medicinal chemistry group at a large pharma firm. He brings expertise in central nervous system, oncology, virology, and anti-inflammatory drug discovery programs.
TK
Tucker KellyinChief Financial Officer
CK
Chris KenneyinChief Medical OfficerChris Kenney is a board-certified neurologist with extensive clinical research experience in academic and industry settings, including leadership roles in pharmaceutical drug development across multiple stages. He brings expertise in clinical development, product launches, and regulatory compliance, with deep experience across neurological and psychiatric disorders including epilepsy, depression, and movement disorders.
SM
Shelley McCloskeyinExecutive Vice President, Human Resources
MD
Matthew D. RonsheiminChief Operating OfficerMatthew D. Ronsheim is Chief Operating Officer at Xenon Pharma, a neuroscience-focused biopharmaceutical company developing ion channel modulators for neurological and psychiatric disorders. He brings over 25 years of experience in biotechnology and pharmaceutical operations, with background spanning R&D, regulatory affairs, manufacturing, commercial strategy, and organizational leadership across discovery, clinical development, and commercialization phases.
RS
Robin SherringtoninExecutive Vice President, Strategy and InnovationRobin Sherrington is Executive Vice President of Strategy and Innovation at Xenon Pharma, a neuroscience-focused biopharmaceutical company developing ion channel modulators for neurological and psychiatric disorders. He has held business development and scientific roles focused on strategic partnerships in biotechnology and pharmaceuticals.
Investors · 3
Valuation · disclosed
Disclosed events$122.2Mvaluation at IPONov 2014 · $9.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Xenon Pharma do?
- Xenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders. Its pipeline includes a Phase 3 program in epilepsy and depression for its lead candidate azetukalner, along with early-stage pain programs targeting sodium and potassium channels.
- Who are Xenon Pharma's investors?
- Xenon Pharma's investors include Avoro Capital Advisors, Foresite Capital, New Enterprise Associates (NEA).